Table 2: Some marketed or in clinical trials of nano-preparations.
|
Name of drug |
Active ingredient |
Dosage form route of administration |
Year of Listing |
Marketing status |
Company |
Remarks |
|
Doxil® |
Adriamycin |
Injection; Intravenous injection |
1995 |
RX |
Sequus pharmaceuticals |
RLD |
|
Rapamune® |
Sirolimus |
Tablet; Oral |
2000 |
RX |
PF prism CV |
RLD |
|
Emend® |
Aprepitant |
Capsule; Oral |
2003 |
RX |
Merck |
RLD |
|
Tricor® |
Fenofibrate |
Tablet; Oral |
2004 |
RX |
Abbvie |
RLD |
|
Triglide® |
Fenofibrate |
Tablet; Oral |
2005 |
RX |
Skyepharma AG |
RLD |
|
Megace ES® |
Megestrol |
Suspension; Oral |
2005 |
RX |
Endopharms inc |
RLD |
|
Liporaxel® |
paclitaxel |
Solution; Oral |
2016 |
RX |
Haihe Biopharma |
Listed in Korea |
|
Rybelsus® |
Semaglutide |
Tablet; Oral |
2019 |
RX |
Novo |
RLD |